DC
REGN icon

Diametric Capital’s Regeneron Pharmaceuticals REGN Stock Holding History

Diametric Capital’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-437
Closed -$246K – 478
2025
Q3 		$246K Buy
+437
New +$247K 0.09% 275
2020
Q1 		– Sell
-2,846
Closed -$1.07M – 160
2019
Q4 		$1.07M Buy
+2,846
New +$958K 0.78% 50
2019
Q3 		– Sell
-4,463
Closed -$1.4M – 131
2019
Q2 		$1.4M Buy
4,463
+3,540
+384% +$1.18M 0.89% 42
2019
Q1 		$374K Sell
923
-2,684
-74% -$1.11M 0.29% 76
2018
Q4 		$1.35M Buy
+3,607
New +$1.32M 1.04% 44

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Diametric Capital's REGN Position: Q4 2025 in Review

Diametric Capital sold out of Regeneron Pharmaceuticals (REGN) in Q4 2025, closing a stake of 437 shares — an estimated $246K sold.

Diametric Capital first reported a position in REGN in Q4 2018 and held it in 5 quarters. The position peaked at $1.4M in Q2 2019. 1,385 funds tracked by Wall St. Rank hold REGN as of Q4 2025.

  • Diametric Capital reported no remaining Regeneron Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Diametric Capital sold 437 Regeneron Pharmaceuticals shares in Q4 2025, an estimated $246K.
  • Diametric Capital first reported a position in Regeneron Pharmaceuticals in Q4 2018 and held it in 5 quarters.
  • Diametric Capital's Regeneron Pharmaceuticals position peaked at $1.4M in Q2 2019.
  • 1,385 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2025.

Based on Diametric Capital's 13F filing for Q4 2025, filed 13 Feb 2026.